albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study. (PubMed, EBioMedicine) - "The combination of nab-paclitaxel and cisplatin administered by PIPAC was safe and well tolerated in patients with peritoneal carcinomatosis. Further investigation of this combination is warranted."

Journal • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pain • Pancreatic Cancer • Peritoneal Cancer • Solid Tumor

TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - P3 | N=190 | Active, not recruiting | Sponsor: RenovoRx | Recruiting ➔ Active, not recruiting

Enrollment closed • Neutropenia • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy (clinicaltrials.gov) - P2/3 | N=160 | Recruiting | Sponsor: Guangdong Provincial People's Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2026 ➔ Sep 2026

Enrollment open • Trial initiation date • Breast Cancer • Oncology • Solid Tumor

Cutaneous metastasis as the initial presentation of pancreatic adenocarcinoma (EADV 2026) - "Subsequent imaging studies identified a pancreatic tail mass with hepatic, pulmonary, and bone metastases, establishing the diagnosis of metastatic pancreatic adenocarcinoma.The patient initiated palliative chemotherapy with gemcitabine and nab-paclitaxel but experienced rapid disease progression and died shortly thereafter, reflecting the poor prognosis associated with cutaneous dissemination of pancreatic cancer. Published data indicate that median survival after diagnosis of cutaneous metastasis from pancreatic adenocarcinoma is typically less than six months, as observed in this case.This case emphasizes that atypical, rapidly progressive cutaneous lesions - particularly in elderly patients with systemic symptoms - should prompt consideration of an underlying visceral malignancy. Early skin biopsy, appropriate immunohistochemical evaluation, comprehensive staging, and multidisciplinary collaboration are essential for establishing the diagnosis, guiding management,..."

Hematological Malignancies • Lymphoma • Oncology • Pancreatic Adenocarcinoma • MUC16

A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) (clinicaltrials.gov) - P3 | N=436 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Georgetown University | Trial primary completion date: Dec 2026 ➔ Aug 2027

Trial primary completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. (PubMed, ESMO Open) - "NALIRIFOX improved mPDAC survival versus Gem + NabP irrespective of patient age, with no signals for reduced tolerability in the older (versus younger) patients. The results provide reassurance that triplet therapy with NALIRIFOX is an efficacious and tolerable regimen in older treatment-naive patients with mPDAC who were fit enough for inclusion in NAPOLI 3, supporting consideration of its use as 1L therapy in this population."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. (PubMed, Nat Commun) - P2 | "MCGN also induced tumor inflammation as confirmed by tissue staining and T cell rescue. A multicenter randomized phase 2 trial comparing MCGN to GN in patients with treatment-naïve metastatic PDA is ongoing."

Journal • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CXCL12 • CXCR4

PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Real-World Survival Outcomes Associated with Standard Versus Modified Gemcitabine/Nab-Paclitaxel Dosing Schedules in Metastatic Pancreatic Cancer (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Oncology • Pancreatic Cancer • Solid Tumor

First-line FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence (ESMO 2026) - No abstract available

HEOR • Metastases • Real-world • Real-world evidence • Retrospective data • Review • Oncology • Pancreatic Cancer • Solid Tumor

Avutometinib plus defactinib (AvDf) with or without gemcitabine and nab-Paclitaxel (GnP) in previously treated patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations (ESMO 2026) - No abstract available

Clinical • Oncology • Pancreatic Ductal Adenocarcinoma • KRAS

Stromal caveolin-1 expression and efficacy of nab-paclitaxel + ramucirumab in unresectable gastric cancer: a multicentre retrospective study in Japan (WJOG18824G/CAPPUCCINO) (ESMO 2026) - No abstract available

Retrospective data • Stroma • Gastric Cancer • Oncology • Solid Tumor • CAV1

Association of SPARC Expression With the Efficacy of Carboplatin Plus Nab-Paclitaxel and Docetaxel in Squamous Lung Cancer: An Ancillary Study of the CAPITAL Study (CJLSG2402) (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • SPARC

Surufatinib Combined with Toripalimab and Nab-paclitaxel/gemcitabine Chemotherapy as First-Line Treatment for Advanced Pancreatobiliary-Type Ampullary Carcinoma: A Prospective Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ampulla of Vater Carcinoma • Oncology

A phase II trial of gemcitabine, cisplatin, nab-paclitaxel, and durvalumab as first-line treatment for advanced gallbladder cancer: An interim analysis (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Gallbladder Cancer • Oncology • Solid Tumor

Envafolimab Plus Nab-Paclitaxel and Platinum as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): An Open-Label, Single-Arm, Phase II Trial (ESMO 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Trial In Progress- MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P3 data • Oncology • Pancreatic Ductal Adenocarcinoma

Liquid biopsy of cancer-associated fibroblasts (CAFs) and tumor fibrosis for assessment of response and survival in pancreas cancer patients treated with Nivolumab/radiotherapy ± Ipilimumab or Gemcitabine/Nab-Paclitaxel ± Tocilizumab (ESMO 2026) - No abstract available

Biopsy • Clinical • Liquid biopsy • Oncology • Pancreatic Cancer • Solid Tumor • CAFs

TQB2868 Plus Nab-Paclitaxel/Gemcitabine ± Anlotinib as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: A Prospective Multicenter Two-Cohort Phase II Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

Six Weeks of Induction Gemcitabine Plus Nab Paclitaxel (AG) Followed by Sequential Surufatinib Plus AG or AG alone as First Line Therapy for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): A Single Center, Two Cohort, Phase II Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

PRIMUS-001: An adaptive phase 2 study of FOLFOX-A (FOLFOX/nab-paclitaxel) versus AG (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic cancer, with biomarker evaluation (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel for borderline resectable pancreatic cancer: a prospective single-arm phase II trial (ESMO 2026) - No abstract available

Clinical • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor